Gemoscan Canada, Inc. Announces Grants of Stock Options

Gemoscan Canada, Inc. Announces Grants of Stock Options

TORONTO, March 21, 2013 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. (TSX-V:GES)
(MUN:1GE) ("Gemoscan" or the "Company"), a leading owner and marketer of food
sensitivity and dietary management solutions, announces that, subject to
regulatory approval, its Board of Directors has approved, effective March 20,
2013, the grant of an aggregate of 645,000 stock options (the "Options") to
directors, officers and employees of the Corporation. The Options are
exercisable into Class A shares of Gemoscan at an exercise price of $0.14 per
share.The Options all vest immediately and have a five year term to expiry.

About Gemoscan Canada, Inc.

Gemoscan is an industry leader in food intolerance management and maintains a
first-to- market position with Canada wide distribution through select retail
partners. Founded in 2003, using its proprietary patented technology, Gemoscan
develops, owns and markets comprehensive food sensitivity and dietary
management solutions for consumers, including the HEMOCODE™ Food Intolerance
System and the MenuWise™ Food Intolerance Plan, personalized naturopathically
supervised nutritional programs that promote well-being. Gemoscan is the first
and only provider to commercialize a food intolerance management solution
directly to consumers in partnership with retailers, and today offers the most
comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under
the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock
Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available
to Gemoscan. Forward- looking statements are subject to a number of signify
cant risks and uncertainties and other factors that may cause the actual
results of Gemoscan to differ materially from those discussed in the forward-
looking statements, and even if such actual results are realized or
substantially realized, there can be no assurance that they will have the
expected consequences to, or effects on Gemoscan. Any forward-looking
statement speaks only as of the date on which it is made and, except as may be
required by applicable securities laws, Gemoscan disclaims any intent or
obligation to update any forward- looking statement, whether as a result of
new information, future events or results or otherwise. Although Gemoscan
believes that the assumptions inherent in the forward-looking statements are
reasonable, forward-looking statements are not guarantees of future
performance and accordingly undue reliance should not be put on such
statements due to the inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

CONTACT: Company:
         Brian Kalish
         Chief Executive Officer
         Gemoscan Canada, Inc.
         416.650.1200
         bkalish@hemocode.com
         www.gemoscan.com
        
         Media:
         Leonard Zehr
         Kilmer Lucas Inc.
         T: (416) 833-9317
         leonard@kilmerlucas.com